GlassScriptPhysician profile
Alpesh Desai
NPI 1386696904
$1,568,254.93
in general payments reported to CMS, 2019-2025
35 companies · $230K in 2025
The $230K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $62K · 2021: $93K · 2022: $157K · 2023: $189K · 2024: $744K · 2025: $230K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $573K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $487K · Travel and Lodging: $80K · Consulting Fee: $13K · Food and Beverage: $11K · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $573,060.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $486,762.17 |
| Travel and Lodging | $79,844.50 |
| Consulting Fee | $12,601.00 |
| Food and Beverage | $10,713.83 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Skye Orthobiologics LLC | $573,060.00 | 2024 | |
| Abbvie INC. | $293,656.78 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $291,067.45 | 2021-2025 | Dupixent |
| Genzyme Corporation | $152,104.89 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $109,088.61 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $99,855.36 | 2019-2025 | |
| Janssen Biotech, INC. | $38,154.38 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $10,124.62 | 2020-2025 | Odomzo, Blu-U |
| Leo Pharma INC. | $210.14 | 2022-2025 | Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $206.55 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $109.84 | 2023-2025 | Zoryve |
| Revance Therapeutics, INC. | $107.20 | 2025 | Daxxify |
| Strata Skin Sciences, INC. | $83.59 | 2022-2025 | Xtrac |
| Galderma Laboratories, L.P. | $80.66 | 2025 | Nemluvio, Aklief |
| Amgen INC. | $77.41 | 2023-2025 | Otezla, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.16 | 2023-2025 | |
| Allergan, INC. | $47.53 | 2021-2022 | |
| Organon LLC | $28.96 | 2025 | |
| Ucb, INC. | $21.98 | 2023 | Cimzia |
| Helsinn Therapeutics (U.S.), INC. | $21.56 | 2023 | Valchlor |
| Biofrontera INC. | $20.86 | 2025 | |
| Dusa Pharmaceuticals, INC. | $19.43 | 2019 | |
| Botanix Sb INC | $16.59 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $15.32 | 2023 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $14.06 | 2025 | Clindacin Etz, Genadur |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alpesh Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.